The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Molecular genetics of early-onset Alzheimer’s disease revisited
Open accessAbstract
As the discovery of the Alzheimer's disease (AD) genes, APP, PSEN1, and PSEN2, in families with autosomal dominant early-onset AD (EOAD), gene discovery in familial EOAD came more or less to a standstill. Only 5% of EOAD patients are carrying a pathogenic mutation in one of the AD genes or a apolipoprotein E (APOE) risk allele ε4, most of EOAD patients remain unexplained. Here, we aimed at summarizing the current knowledge of EOAD genetics and its role in ongoing approaches to understand the biology of AD and disease symptomatology as well as developing new therapeutics. Next, we explored the possible molecular mechanisms that might underlie the missing genetic etiology of EOAD and discussed how the use of massive parallel sequencing technologies triggered novel gene discoveries. To conclude, we commented on the relevance of reinvestigating EOAD patients as a means to explore potential new avenues for translational research and therapeutic discoveries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These rare mutations cause the aggregation of amyloid proteins, leading to the progression of early onset AD.”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [157]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“But it was until 1980s that three genes, including APP, PSEN1, and PSEN2, were found to be responsible for early onset AD.157”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [157]
Experimental — accuracy not yet measuredIn the citing paper
“PSEN2 mutations are much rarer, with only around 30 mutations identified in ADAD families [2].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [2]
In the citing paper
“A majority of ADAD families carry a pathogenic mutation in one of three genes: APP, presenilin 1 (PSEN1), or presenilin 2 (PSEN2) [2, 33].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [2]
In the citing paper
“To date, more than 50 highly penetrant mutations have been identified in APP [2].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [2]
In the citing paper
“ADAD is very rare, accounting for less than <1% of all cases of AD [2, 31–33]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [2]
In the citing paper
“While mutations in these genes are the most well-studied mutations associated with EOAD, it is estimated that a significant portion of EOAD remains unexplained genetically [2].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [2]
In the citing paper
“Gene duplications of APP are well-known to cause AD, with as many as 25 duplications of variable length associated with AD in EOAD families [2]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [2]
In the citing paper
“The large variability in the age at onset of AD symptoms even among families who share common pathogenic mutations [31]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–617 of 617
Moreira-de-Sá, A. (2024) · theses.fr (ABES) · doi:10.70675/3e418ab2ze9a3z43e4z9d87ze5870aefddac
Funakawa, K., Kurihara, M., Takahashi, K., Ihara, R., Kakumoto, T., Ishibashi, K., Ishii, K., Fujii, Y., Kobayashi, S., & Iwata, A. (2026) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-002216
Advances and Limitations of Rodent Models in Alzheimer’s Disease Pathogenesis and Therapeutics
Singh, A., & Duerner, L. (2026) · Science Discovery Medicine · doi:10.11648/j.sdmed.20260102.14
Íñiguez, M., Tobias, B. M., López-Alava, S., Yuste, S., Manzano, J. I., Recio‐Fernández, E., Pérez‐Matute, P., & Motilva, M. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-04011-w · Cited by 1
The role of YKL-40 in Alzheimer’s disease pathology and drug targeting
Sha, Y., Fu, H., Lu, K., Wang, G., & Wang, Y. (2026) · PeerJ · doi:10.7717/peerj.21361
Soncini, C., Chiari, A., Martini, N., Costanzini, S., Despini, F., Tondelli, M., Zamboni, G., Teggi, S., Vinceti, M., & Filippini, T. (2026) · Albanian Journal of Natural and Technical Sciences · doi:10.67537/ajnts3101005
The past, present, and future of Alzheimer's disease—part 3: the future
Nitríni, R., Takada, L. T., & Brucki, S. M. D. (2026) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0046-1824435
Lawal, A. O., Jacob, I. B., Karnik, V., Fan, H., Thangamani, S., Massa, P. T., & Wang, G. (2026) · Viruses · doi:10.3390/v18070783
Morris, S. A. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261472068
Yang, F., Gao, W., Wang, J. Z., & Li, H. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06098-y
Reprogramming lipid metabolism in virus-infected neuronal cellsPreprint
Li, L.-Z., Qu, H.-R., Fu, W., & Feng, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10472222/v1
Burdman, G., Hanna, M., Yndart, A., Vashist, A., & Lakshmana, M. K. (2026) · Cells · doi:10.3390/cells15191768
Mandić‐Stojmenović, G., Kostić, V., Marjanović, A., Novaković, I. V., Aleksić, P., Stojković, T., & Stefanova, E. D. (2026) · Diseases · doi:10.3390/diseases14100359
Association of TOMM40 polymorphisms with Alzheimer's disease risk in an Iranian population
Ghaderpanah, M., Nejad, J. H., & Gharechahi, J. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102661
Potential links between PCOS/PMOS and Alzheimer disease and related dementias
Amiri, M., Hamidi, A. K., Farkas, D. L., Buyalos, R. P., & Azziz, R. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag206
Alzheimer’s Disease: Contemporary Diagnosis and Treatment
Puthota, J., Hasoğlu, T., Salinas, J., & Forester, B. P. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20260012
Hauser, W., Keller, J. E., Pasnoor, M., & Wright, D. E. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1854989
Metadata
- Authors
- Cacace, R., Sleegers, K., & Van Broeckhoven, C.
- Affiliations
- University of Antwerp (BE)
- Neurodegenerative Brain Diseases group Department of Molecular Genetics VIB Antwerp Belgium
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-03-23
- Volume
- 12
- Issue
- 6
- Pages
- 733-748
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2306696647
- Cited by
- 617
- References
- 167
- Citations by year
- 2026: 34 · 2025: 71 · 2024: 60 · 2023: 90 · 2022: 85 · 2021: 88 · 2020: 61 · 2019: 49 · 2018: 35 · 2017: 32 · 2016: 11
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Fonds Wetenschappelijk Onderzoek
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- early-onset Alzheimer's disease, familial Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Humans, Models, Molecular, Molecular Biology, Mutation, Amyloid beta-Protein Precursor, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
